Literature DB >> 24091745

Genetic diversity of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates and the first identification of serotype 20B in China.

Q Guo1, C Zhuo, Y Xu, W Huang, C Wang, S Zhang, J Huang, F Hu, D Zhu, F Yang, M Wang.   

Abstract

The purpose of this study was to investigate the genetic characteristics of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates in China. A total of 377 S. pneumoniae clinical isolates, including 307 pediatric strains and 70 adult strains, were collected from eight centers in China. The minimal inhibitory concentrations (MICs) of 10 antimicrobial agents were determined by agar dilution. Multilocus sequence typing (MLST), serotyping, and quinolone resistance-determining region (QRDR) variations were conducted in levofloxacin-nonsusceptible isolates by polymerase chain reaction (PCR)-based methods. Seven levofloxacin-nonsusceptible isolates were found, with an overall resistance rate of 1.9 % (7/377) and 8.6 % (6/70) in adults. Sequence analyses of parC, gyrA, and parE QRDRs in levofloxacin-resistant isolates demonstrated mutations in dual target sites at the hot spots. These seven strains represented multiple clones: two strains were serotype 19F (Taiwan(19F)-14) and MLST clonal complex (CC) 271/320, two were typed as 23F (Spain(23F)-1) and CC81, two were determined as serotype 20B and a new sequence type of ST6935, and one non-serotypeable pediatric strain belonged to a new sequence type of ST6946. Two serotype 19F strains possessed a variety of characteristic alterations of viridans group streptococci in gyrA (Ser114Gly) or parC (Ser52Gly, Asn91Asp). Fluoroquinolone-nonsusceptible S. pneumoniae isolates showed a substantial degree of genetic diversity and belonged to pre-existing epidemic clones together with native clones. S. pneumoniae strains with serotype 20B was recovered for the first time to be associated with levofloxacin resistance in China.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091745     DOI: 10.1007/s10096-013-1979-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Characterization of highly antimicrobial-resistant clinical pneumococcal isolates recovered in a Chinese hospital during 2009-2010.

Authors:  Bo Zhang; Robert E Gertz; Zhiyong Liu; Zhongya Li; Weiling Fu; Bernard Beall
Journal:  J Med Microbiol       Date:  2011-08-26       Impact factor: 2.472

2.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 3.  A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.

Authors:  Jeffrey D Fuller; Donald E Low
Journal:  Clin Infect Dis       Date:  2005-05-26       Impact factor: 9.079

4.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.

Authors:  P L Ho; W S Tse; K W Tsang; T K Kwok; T K Ng; V C Cheng; R M Chan
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

5.  eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data.

Authors:  Edward J Feil; Bao C Li; David M Aanensen; William P Hanage; Brian G Spratt
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

6.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease.

Authors:  Mark C Enright; Brian G Spratt
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

7.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

Authors:  Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney
Journal:  J Infect Dis       Date:  2007-10-04       Impact factor: 5.226

8.  High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Authors:  Jae-Hoon Song; Sook-In Jung; Kwan Soo Ko; Na Young Kim; Jun Seong Son; Hyun-Ha Chang; Hyun Kyun Ki; Won Sup Oh; Ji Yoeun Suh; Kyong Ran Peck; Nam Yong Lee; Yonghong Yang; Quan Lu; Anan Chongthaleong; Cheng-Hsun Chiu; M K Lalitha; Jennifer Perera; Ti Teow Yee; Gamini Kumarasinghe; Farida Jamal; Adeeba Kamarulzaman; Navaratnam Parasakthi; Pham Hung Van; Celia Carlos; Thomas So; Tak Keung Ng; Atef Shibl
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

Authors:  R Canton; M Morosini; M C Enright; I Morrissey
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

10.  Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.

Authors:  Adela G de la Campa; Luz Balsalobre; Carmen Ardanuy; Asunción Fenoll; Emilio Pérez-Trallero; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  2 in total

Review 1.  Diffuse axonal injury after traumatic cerebral microbleeds: an evaluation of imaging techniques.

Authors:  Jun Liu; Zhifeng Kou; Yongquan Tian
Journal:  Neural Regen Res       Date:  2014-06-15       Impact factor: 5.135

2.  Characteristics of serogroup 20 S.pneumoniae isolates from Brazil.

Authors:  Juliana Caierão; Fernando Hayashi Sant'Anna; Paulina Hawkins; Gabriela Rosa Cunha; Mariana Mott; Diego Rodrigues Falci; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  BMC Infect Dis       Date:  2016-08-15       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.